Literature DB >> 12454160

Use of subtractive hybridization to identify a diagnostic probe for a cystic fibrosis epidemic strain of Pseudomonas aeruginosa.

Yasmin N Parsons1, Stavroula Panagea, Catherine H M Smart, Martin J Walshaw, C Anthony Hart, Craig Winstanley.   

Abstract

A multiresistant strain of Pseudomonas aeruginosa is widespread among cystic fibrosis (CF) patients attending clinics in Liverpool, United Kingdom. Suppression subtractive hybridization was used to identify sequences present in the Liverpool CF epidemic strain but absent from strain PAO1. Using dot blot and PCR amplification assays, the prevalence of such sequences among a panel of CF isolates was determined. Several sequences were found only in the Liverpool epidemic strain. Some sequences were present in the Liverpool epidemic strain and in a minority of other isolates, including sequences with homology to genes implicated in O6 serotype and siderophore production. The Liverpool epidemic strain and 81% of nonepidemic isolates contained a sequence identified as part of the PAGI-1 genomic island. Other strains implicated in epidemic spread, which were from Manchester, United Kingdom, and Melbourne, Australia, were also screened. None of the sequences identified was present in the Manchester strain. However, one of two Melbourne strains contained some of the sequences found in the Liverpool epidemic strain. All isolates implicated in epidemic spread and 76% of sporadic isolates contained the exoS gene. A sequence present in all isolates of the Liverpool epidemic strain was used to develop a diagnostic PCR test for identification of the strain from colonies or directly from sputum samples.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454160      PMCID: PMC154653          DOI: 10.1128/JCM.40.12.4607-4611.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Suppression subtractive hybridization: a versatile method for identifying differentially expressed genes.

Authors:  L Diatchenko; S Lukyanov; Y F Lau; P D Siebert
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

2.  Functional analysis of genes responsible for the synthesis of the B-band O antigen of Pseudomonas aeruginosa serotype O6 lipopolysaccharide.

Authors:  M Bélanger; L L Burrows; J S Lam
Journal:  Microbiology       Date:  1999-12       Impact factor: 2.777

3.  Identification of a genomic island present in the majority of pathogenic isolates of Pseudomonas aeruginosa.

Authors:  X Liang; X Q Pham; M V Olson; S Lory
Journal:  J Bacteriol       Date:  2001-02       Impact factor: 3.490

4.  Study of pyoverdine type and production by Pseudomonas aeruginosa isolated from cystic fibrosis patients: prevalence of type II pyoverdine isolates and accumulation of pyoverdine-negative mutations.

Authors:  D De Vos; M De Chial; C Cochez; S Jansen; B Tümmler; J M Meyer; P Cornelis
Journal:  Arch Microbiol       Date:  2001-05       Impact factor: 2.552

5.  Epidemic population structure of Pseudomonas aeruginosa: evidence for a clone that is pathogenic to the eye and that has a distinct combination of virulence factors.

Authors:  J A Lomholt; K Poulsen; M Kilian
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

6.  Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P aeruginosa.

Authors:  S J McCallum; J Corkill; M Gallagher; M J Ledson; C A Hart; M J Walshaw
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

7.  Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic.

Authors:  A M Jones; J R Govan; C J Doherty; M E Dodd; B J Isalska; T N Stanbridge; A K Webb
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

8.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Authors:  C K Stover; X Q Pham; A L Erwin; S D Mizoguchi; P Warrener; M J Hickey; F S Brinkman; W O Hufnagle; D J Kowalik; M Lagrou; R L Garber; L Goltry; E Tolentino; S Westbrock-Wadman; Y Yuan; L L Brody; S N Coulter; K R Folger; A Kas; K Larbig; R Lim; K Smith; D Spencer; G K Wong; Z Wu; I T Paulsen; J Reizer; M H Saier; R E Hancock; S Lory; M V Olson
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

9.  Detection of bacterial virulence genes by subtractive hybridization: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant.

Authors:  S L Reckseidler; D DeShazer; P A Sokol; D E Woods
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

10.  High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

Authors:  A Oliver; R Cantón; P Campo; F Baquero; J Blázquez
Journal:  Science       Date:  2000-05-19       Impact factor: 47.728

View more
  17 in total

1.  A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance.

Authors:  Prabhakar Salunkhe; Catherine H M Smart; J Alun W Morgan; Stavroula Panagea; Martin J Walshaw; C Anthony Hart; Robert Geffers; Burkhard Tümmler; Craig Winstanley
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

2.  Identification of Pseudomonas aeruginosa-induced genes in human mast cells using suppression subtractive hybridization: up-regulation of IL-8 and CCL4 production.

Authors:  Genlou Sun; Fang Liu; Tong-Jun Lin
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

3.  Isolation and characterization of a harvest-inducible gene hi11 and its promoter from alfalfa.

Authors:  Jian Zhang; Ai-Sheng Xiong; Larry R Erickson
Journal:  Mol Biol Rep       Date:  2010-03-18       Impact factor: 2.316

Review 4.  Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Authors:  Michael D Parkins; Ranjani Somayaji; Valerie J Waters
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

5.  Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.

Authors:  Ryka Moore; Jennelle M Kyd; Rosemary Carzino; Davide Armstrong; Keith Grimwood; Diana C Otczyk; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

6.  Development and Validation of a PCR Assay To Detect the Prairie Epidemic Strain of Pseudomonas aeruginosa from Patients with Cystic Fibrosis.

Authors:  M Workentine; A Poonja; B Waddell; J Duong; D G Storey; D Gregson; R Somayaji; H R Rabin; M G Surette; M D Parkins
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

7.  A diagnostic PCR assay for the detection of an Australian epidemic strain of Pseudomonas aeruginosa.

Authors:  Heidi L Williams; Lynne Turnbull; Susan J Thomas; Anna Murphy; Tim Stinear; David S Armstrong; Cynthia B Whitchurch
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-07-16       Impact factor: 3.944

8.  Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa.

Authors:  Craig Winstanley; Morgan G I Langille; Joanne L Fothergill; Irena Kukavica-Ibrulj; Catherine Paradis-Bleau; François Sanschagrin; Nicholas R Thomson; Geoff L Winsor; Michael A Quail; Nicola Lennard; Alexandra Bignell; Louise Clarke; Kathy Seeger; David Saunders; David Harris; Julian Parkhill; Robert E W Hancock; Fiona S L Brinkman; Roger C Levesque
Journal:  Genome Res       Date:  2008-12-01       Impact factor: 9.043

9.  PCR-based detection of a cystic fibrosis epidemic strain of Pseudomonas Aeruginosa.

Authors:  Stavroula Panagea; Craig Winstanley; Yasmin N Parsons; Martin J Walshaw; Martin J Ledson; C Anthony Hart
Journal:  Mol Diagn       Date:  2003

10.  Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients.

Authors:  M Al-Aloul; J Crawley; C Winstanley; C A Hart; M J Ledson; M J Walshaw
Journal:  Thorax       Date:  2004-04       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.